Form 4: Zenas BioPharma CFO Jennifer Fox Reports Stock Acquisition

Zenas BioPharma CFO Jennifer Fox acquired 1,592 shares via an employee stock plan and was granted 125,000 stock options.

Summary

• Jennifer A. Fox, Chief Business Officer and CFO of Zenas BioPharma, Inc., reported the acquisition of 1,592 shares of common stock.
• The shares were acquired on February 5, 2026, through the company's 2024 Employee Stock Purchase Plan at a price of $13.35 per share.
• Additionally, the reporting person was granted 125,000 stock options on June 15, 2026, with an exercise price of $18.71 per share.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral, routine regulatory disclosure regarding executive compensation and equity ownership.

Positives

• Alignment of executive interests with shareholders through increased equity ownership.
• Participation in the company's Employee Stock Purchase Plan indicates executive confidence in the firm's long-term value.

Negatives

• None identified; this is a standard regulatory disclosure of executive compensation and equity participation.

Risks

• Vesting of stock options is subject to continued service, creating potential retention risk if the executive departs.
• Market price volatility could impact the value of the acquired shares and the future exercise value of the options.

Future Outlook

The options vest over a four-year period, with 25% vesting on June 15, 2027, and the remainder in equal monthly installments over the following 36 months.

Management Comments

• The filing does not contain narrative management commentary.

Industry Context

StockSavvy.ai notes that standard equity grants and ESPP participation for C-suite executives in the biotech sector are common practices used to incentivize long-term performance and retention.

Comparison to Industry Standards

• The vesting schedule of 25% after one year followed by monthly installments is consistent with standard industry practices for executive equity compensation.
• The use of Rule 10b5-1(c) and standard ESPP participation aligns with typical corporate governance protocols for publicly traded biotech firms.

Legal Proceedings

• None

Related Party Transactions

• None

Stakeholder Impact

• Positive signal to shareholders regarding executive commitment to the company's future.

Next Steps

• Vesting of 25% of the 125,000 stock options on June 15, 2027.

Key Dates

Keywords

Zenas BioPharma, ZBIO, Form 4, Insider Trading, Executive Compensation, Stock Options, Biotech